Swiss MedTech 2026: CHF 21.4B, 95% Exported — 8–14× EBITDA

1.0Market Snapshot

CHF 21.4B: Swiss medtech sector revenue (Swiss Medtech association), making Switzerland one of the largest medtech exporters per capita globally
~1,400: Medical device and medtech companies operating in Switzerland (Swiss Medtech Industry Report)
~67,500: Direct employment in the Swiss medtech sector (Swiss Medtech association). Additional indirect employment estimated at 54,000+
~95%: Share of Swiss medtech production exported, reflecting the small domestic market and global competitiveness
+6.5%: Annual revenue growth rate of the Swiss medtech sector (Swiss Medtech association / SMTI report)

According to Val Index analysis of Swiss commercial-register and federal data (2026), the Swiss medtech & medical devices market is worth CHF 21.4B — Swiss medtech sector revenue (Swiss Medtech association), making Switzerland one of the largest medtech exporters per capita globally.

According to Val Index analysis of Swiss commercial-register and federal data (2026), ~95% of Swiss medtech & medical devices output is exported (Share of Swiss medtech production exported, reflecting the small domestic market and global competitiveness).

According to Val Index analysis of Swiss commercial-register and federal data (2026), Switzerland counts ~1,400 medtech & medical devices companies — Medical device and medtech companies operating in Switzerland (Swiss Medtech Industry Report).

What is a medtech & medical devices business worth? →

2.0Industry Overview

Market Scope

Switzerland is a global medtech powerhouse with the highest medical technology patent density in Europe. The sector generates CHF 21.4 billion in annual revenue, employs approximately 67,500 people across around 1,400 companies, and exports roughly 95% of its production. The country hosts several global leaders: Straumann (dental implants, CHF 2.3B revenue, Basel), Sonova (hearing aids and audiological care, CHF 3.7B revenue, Stäfa ZH), Ypsomed (injection and infusion systems, Burgdorf BE), Medela (breast pumps and medical vacuum technology, Baar ZG), and Bien-Air Surgery (dental and surgical micromotors, Biel BE).

3.0Industry Health Check (SWOT)

Key opportunityDigital health and connected medical devices

Internal factors

Strengths5

Highest medtech patent density in Europe — Switzerland leads in per-capita medical device innovation (EPO data)

Weaknesses5

EU MDR transition (since May 2021) has increased regulatory compliance costs by 30-50%, disproportionately burdening SMEs→ §5.0

External factors

Opportunities5

Digital health and connected medical devices: IoT-enabled implants, remote patient monitoring, and wearable diagnostics→ §4.0

Threats5

EU MDR Notified Body capacity shortage creating 18-24 month certification backlogs, delaying product launches→ §4.0

Sector Outlook

DefensiveBalancedGrowth

4.0Key Trends

EU MDR Compliance Costs Reshaping the Industry

50%

The EU Medical Device Regulation (MDR), in force since May 2021, has fundamentally changed the cost structure for Swiss medtech companies. Regulatory compliance costs have risen by 30-50%, with smaller firms facing the heaviest burden. The shortage of EU Notified Bodies has created 18-24 month certification backlogs, forcing companies to delay product launches or discontinue legacy devices. An estimated 25-30% of lower-revenue medical devices have been withdrawn from the European market rather than being re-certified under MDR. For Swiss manufacturers, the absence of a domestic Notified Body means full dependence on EU institutions, adding logistical complexity and political risk tied to the Swiss-EU MRA framework.

Digital Health & Connected Medical Devices

15%

The convergence of IoT, cloud computing, and miniaturized sensors is transforming Swiss medtech. Sonova's hearing aids now feature Bluetooth streaming and AI-driven sound optimization. Ypsomed is developing connected pen injectors that transmit dosage data to patient apps. Smart implants with embedded sensors enable real-time monitoring of healing processes. The Swiss digital health market is projected to grow at 12-15% annually, driven by demand for remote patient monitoring, telehealth integration, and data-driven treatment optimization. ETH Zürich and EPFL are key contributors to biosensor and wearable diagnostic research.

Robotic Surgery & Minimally Invasive Platforms

Robotic-assisted surgery is one of the fastest-growing medtech segments globally, with the market projected to reach USD 20B by 2030. Swiss precision engineering is ideally positioned: companies like Bien-Air Surgery supply high-precision micromotors for robotic surgical systems, while startups such as Distalmotion (Lausanne) have developed modular robotic platforms. The da Vinci ecosystem (Intuitive Surgical) requires thousands of Swiss-made precision components. Orthopedic companies like Mathys AG are integrating robotics-compatible implant designs, and the Basel/Bern corridor is emerging as a hub for surgical robotics R&D.

AI-Powered Diagnostics & Imaging

Artificial intelligence is revolutionizing medical diagnostics, with Swiss companies and research institutions at the forefront. AI algorithms are being deployed in pathology (automated tissue analysis), radiology (CT/MRI interpretation), and ophthalmology (retinal screening). Swiss medtech startups like RetinAI (Bern) and Sophia Genetics (Lausanne, listed NASDAQ) are applying deep learning to medical imaging and genomic diagnostics. The University Hospital of Bern and USZ Zürich are running clinical trials integrating AI diagnostics into routine care. Regulatory frameworks for AI-based Software as a Medical Device (SaMD) are evolving, with Swissmedic working to align with EU and FDA guidance.

5.0Cost Structure Benchmark

22%

30%

20%

10%

Research & Development22%
Personnel30%: Production, Sales, Admin
Materials & Components20%
Quality Assurance & Regulatory Compliance10%
Other Operating Costs8%: Logistics, Facilities, IT
Profit Margin10%: EBITDA

Based on Swiss medtech industry averages (Swiss Medtech association / Deloitte MedTech Study). R&D intensity is notably higher than manufacturing averages (~13% of revenue), reflecting the innovation-driven nature of the sector. EU MDR compliance has added 2-4 percentage points to quality/regulatory costs since 2021.

6.0Top MedTech & Medical Devices Companies in Switzerland

Name	Location	Key Facts
Straumann Group	Basel BS	CHF 2.3B revenue, ~12,200 employees. Global #1 in dental implants and clear aligners (ClearCorrect). Listed on SIX (STMN). Organic growth +8% in 2024. CADCAM digital dentistry platform.
Sonova Holding AG	Stäfa ZH	CHF 3.7B revenue, ~17,000 employees. Global #1 in hearing aids (Phonak, Unitron) and cochlear implants (Advanced Bionics). Listed on SIX (SOON). Operating margin ~20%.
Ypsomed AG	Burgdorf BE	CHF 570M revenue, ~2,200 employees. Leading developer of injection and infusion systems (autoinjectors, pen injectors, insulin pumps). Listed on SIX (YPSN). Partner to major pharma companies.
Medela AG	Baar ZG	Global leader in breast pumps and medical vacuum technology. Family-owned, ~1,800 employees. Active in 100+ countries. Strong in neonatal care and surgical drainage systems.
Bien-Air Surgery SA	Biel BE	High-precision micromotors for dental and surgical applications. Family-owned, ~500 employees. Micro-electromechanical expertise from watchmaking heritage. Key supplier to robotic surgery platforms.
Medartis AG	Basel BS	CHF 220M+ revenue, ~900 employees. Titanium fixation systems for hand, wrist, elbow, and craniomaxillofacial surgery. Listed on SIX (MED). Strong growth in North America.
Mathys AG Bettlach	Bettlach SO	Orthopedic implants (hip, knee, shoulder). Family-owned, ~700 employees. Over 75 years of experience. Active in 30+ countries. Strong in the Solothurn medtech corridor.
u-blox AG	Thalwil ZH	CHF 530M revenue, ~1,500 employees. Global leader in positioning and wireless communication modules. Listed on SIX (UBXN). Key enabler for connected medical devices and IoT health applications.

Straumann Group

Basel BS

CHF 2.3B revenue, ~12,200 employees. Global #1 in dental implants and clear aligners (ClearCorrect). Listed on SIX (STMN). Organic growth +8% in 2024. CADCAM digital dentistry platform.

Sonova Holding AG

Stäfa ZH

CHF 3.7B revenue, ~17,000 employees. Global #1 in hearing aids (Phonak, Unitron) and cochlear implants (Advanced Bionics). Listed on SIX (SOON). Operating margin ~20%.

Ypsomed AG

Burgdorf BE

CHF 570M revenue, ~2,200 employees. Leading developer of injection and infusion systems (autoinjectors, pen injectors, insulin pumps). Listed on SIX (YPSN). Partner to major pharma companies.

Medela AG

Baar ZG

Global leader in breast pumps and medical vacuum technology. Family-owned, ~1,800 employees. Active in 100+ countries. Strong in neonatal care and surgical drainage systems.

Bien-Air Surgery SA

Biel BE

High-precision micromotors for dental and surgical applications. Family-owned, ~500 employees. Micro-electromechanical expertise from watchmaking heritage. Key supplier to robotic surgery platforms.

Medartis AG

Basel BS

CHF 220M+ revenue, ~900 employees. Titanium fixation systems for hand, wrist, elbow, and craniomaxillofacial surgery. Listed on SIX (MED). Strong growth in North America.

Mathys AG Bettlach

Bettlach SO

Orthopedic implants (hip, knee, shoulder). Family-owned, ~700 employees. Over 75 years of experience. Active in 30+ countries. Strong in the Solothurn medtech corridor.

u-blox AG

Thalwil ZH

CHF 530M revenue, ~1,500 employees. Global leader in positioning and wireless communication modules. Listed on SIX (UBXN). Key enabler for connected medical devices and IoT health applications.

7.0Succession & M&A Context

High-Value MedTech M&A

6.0-9.0×: Typical statutory EBITDA multiple
8.0-14.0×: Typical deal EBITDA multiple
Very active: PE interest in Swiss medtech (EQT, Permira, Partners Group)
~1,400: Medtech companies, many family-owned SMEs approaching succession

The Swiss medtech sector is one of the most active M&A markets in the country, driven by three converging forces: (1) global strategic acquirers seeking Swiss precision engineering capabilities and regulatory know-how (e.g., Johnson & Johnson's acquisition of Synthes for USD 21.3B in 2012, the largest Swiss medtech deal ever), (2) private equity firms actively building medtech platforms through buy-and-build strategies, attracted by recurring revenue from consumables and replacement cycles, and (3) a generational succession wave among the many family-owned medtech SMEs in the Bern/Solothurn corridor. Valuations in Swiss medtech remain at a premium: statutory multiples of 6.0-9.0x EBITDA reflect the regulated, IP-rich nature of the sector, while deal multiples of 8.0-14.0x EBITDA are common for companies with strong product portfolios, EU MDR certification, and established distribution networks. PE interest is very active, with firms like EQT, Permira, and Partners Group all making medtech investments in Switzerland.

Market Pulse

Unlock full MedTech & Medical Devices intelligence

Market trends, cost structure, key players, succession analysis and regional clusters for MedTech & Medical Devices — subscribe free to Market Pulse.

Free weekly newsletter. Unsubscribe anytime.

8.0Regional Clusters

Basel Medtech Corridor

Epicenter of Swiss medtech innovation. Home to Straumann (CHF 2.3B), Medartis AG, and dozens of medtech firms. Benefits from proximity to the Basel pharma cluster (Roche, Novartis) and the University of Basel's biomedical research. Strong cross-pollination between pharma and medical devices.

Bern / Solothurn

The Bettlach-Solothurn area alone hosts 60+ medtech firms, including Mathys AG (orthopedic implants) and numerous precision component suppliers. Ypsomed is headquartered in Burgdorf BE. The University of Bern's ARTORG Center is a leading biomedical engineering research institute. Deep precision manufacturing heritage from watchmaking.

Zürich / Eastern Switzerland

Sonova (CHF 3.7B, Stäfa), u-blox (Thalwil), and numerous medtech startups. ETH Zürich drives biomedical engineering, robotics, and digital health research. The Zürich biotech and health-tech startup scene benefits from proximity to University Hospital Zürich (USZ) for clinical validation. Wyss Zurich translational research center.

Romandie

EPFL-driven medtech innovation hub. Distalmotion (robotic surgery, Lausanne), Sophia Genetics (genomic diagnostics, Lausanne, NASDAQ-listed). Bien-Air Surgery in nearby Biel BE. Strong in digital health, AI diagnostics, and surgical robotics. Geneva's international organizations (WHO, GAVI) provide unique global health access.

Sources

Swiss Medtech - Industry Report Swiss Medtech Association Straumann Group - Annual Report Sonova Holding AG - Investor Relations Ypsomed AG - Investor Relations Medartis AG - About ARTORG Center - University of Bern EU MDR - European Commission Medical Devices

ValIndex Intelligence · Alain Walder, M.A. HSG|Data as of 2026-02|8 sources cited

9.0Frequently Asked Questions

▶How much is a MedTech & Medical Devices company worth in Switzerland?

The average Swiss MedTech & Medical Devices company is valued at 6.0 - 9.0× EBITDA on a statutory (tax-based) basis and 8.0 - 14.0× EBITDA in actual deal transactions. The spread between statutory and deal multiples represents a key arbitrage opportunity for informed buyers. The current market trend is rising, with an arbitrage gap rated as high. Actual valuations depend heavily on recurring revenue share, customer diversification, management depth, and equipment modernity.

▶What factors affect the valuation of a MedTech & Medical Devices company?

Key valuation drivers include: Highest medtech patent density in Europe — Switzerland leads in per-capita medical device innovation (EPO data); Global champions headquartered in Switzerland: Straumann (CHF 2.3B, #1 dental implants), Sonova (CHF 3.7B, #1 hearing aids). Factors that can compress valuations include: EU MDR transition (since May 2021) has increased regulatory compliance costs by 30-50%, disproportionately burdening SMEs; Small domestic market (8.8M population) forces immediate internationalization, increasing market entry costs. Deal multiples typically range from 8.0 - 14.0× EBITDA, but actual prices vary significantly based on customer concentration, management quality, revenue predictability, and geographic reach within Switzerland's 26 cantons.

▶How many MedTech & Medical Devices companies are there in Switzerland?

Approximately ~1,400 companies operate in Switzerland's MedTech & Medical Devices sector. Medical device and medtech companies operating in Switzerland (Swiss Medtech Industry Report) The sector employs ~67,500 people and represents a market of CHF 21.4B. Company counts have been evolving due to consolidation trends and succession-driven market exits across Swiss SME sectors.

▶What is the succession situation for MedTech & Medical Devices in Switzerland?

▶What are the key market trends in Swiss MedTech & Medical Devices?

The 4 key trends shaping Swiss MedTech & Medical Devices are: (1) EU MDR Compliance Costs Reshaping the Industry; (2) Digital Health & Connected Medical Devices; (3) Robotic Surgery & Minimally Invasive Platforms; (4) AI-Powered Diagnostics & Imaging. The EU Medical Device Regulation (MDR), in force since May 2021, has fundamentally changed the cost structure for Swiss medtech companies. Regulatory compliance costs have risen by 30-50%, with smalle... These trends directly impact company valuations and M&A activity in the sector.

▶What are the key risks when buying a MedTech & Medical Devices company?

The principal acquisition risks are: (1) EU MDR Notified Body capacity shortage creating 18-24 month certification backlogs, delaying product launches; (2) Rising competition from Asian manufacturers (China, South Korea) improving quality in mid-tier device segments; (3) Increasing pricing pressure from hospital group purchasing organizations and government healthcare budget constraints. Buyers should conduct thorough due diligence on customer concentration, regulatory compliance, and key-person dependencies. Deal multiples of 8.0 - 14.0× EBITDA may be discounted for firms with elevated risk profiles.

▶What is the typical cost structure for Swiss MedTech & Medical Devices companies?

The typical cost breakdown for a Swiss MedTech & Medical Devices firm is: Research & Development: 22%, Personnel (Production, Sales, Admin): 30%, Materials & Components: 20%, Quality Assurance & Regulatory Compliance: 10%, Other Operating Costs (Logistics, Facilities, IT): 8%, Profit Margin (EBITDA): 10%. Based on Swiss medtech industry averages (Swiss Medtech association / Deloitte MedTech Study). R&D intensity is notably higher than manufacturing averages (~13% of revenue), reflecting the innovation-driven nature of the sector. EU MDR compliance has added 2-4 percentage points to quality/regulatory costs since 2021. These benchmarks are important for buyers assessing operational efficiency and margin improvement potential post-acquisition.

▶Which regions are the main MedTech & Medical Devices clusters in Switzerland?

Switzerland's main MedTech & Medical Devices clusters are: (1) Basel Medtech Corridor (BS/BL); (2) Bern / Solothurn (BE/SO); (3) Zürich / Eastern Switzerland (ZH); (4) Romandie (VD/GE). Epicenter of Swiss medtech innovation. Home to Straumann (CHF 2.3B), Medartis AG, and dozens of medtech firms. Benefits from proximity to the Basel ph... Regional concentration affects valuations, as companies in established clusters benefit from supplier ecosystems, specialized talent pools, and industry networks.

MedTech & Medical Devices